View Older Stories View More Recent Stories
-
KeyBanc Starts Hims and Hers (HIMS) at Sector Weight
-
Hims & Hers CEO Dudum comments on Grail investment
-
BofA: 'We maintain our Underperform rating on HIMS due to growing competition, but view this morning’s news positively'
-
Hims & Hers launches menopause treatment services
-
Hims & Hers to Offer Treatments for Menopause, Perimenopause - DJ
-
BofA Negative on Hims and Hers (HIMS): 'Lowering 4Q sales and full year below the guidance range'
-
Hims & Hers releases customer survey data on telehealth care quality
-
Hims & Hers CEO Dudum announces COO change, appointing Mike Chi
-
Hims & Hers names Mike Chi as new COO as Nader Kabbani transitions
-
BofA Reiterating Negative View on Hims and Hers (HIMS): '3Q beat less likely, order growth under more pressure'
-
Survey shows 1/3 of GLP-1 users are lower-income
-
Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
-
GoodRx (GDRX) Lower on Report Trump Officials Weigh Website To Help Shop For Cheaper Drugs
-
Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum: around 100 FDA letters went out last week to companies across the industry, we got one
-
FDA issues warning letter to HIMS over semaglutide marketing claims
-
CMS Launches Landmark $50 Billion Rural Health Transformation Program
-
BofA Securities on Hims and Hers (HIMS): 'Dr. Makary’s op-ed in the New York Times is a negative for HIMS'
-
Hims & Hers shares drop after FDA chief flags ad violations
-
Canaccord Genuity Positive on Hims and Hers (HIMS): 'we see several paths to FY30 targets'
-
BTIG Remains Positive Hims and Hers (HIMS)
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS) 'given near-term competitive pressures in the core business'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $28
-
Hims and Hers (HIMS) PT Lowered to $37 at Truist Securities
-
Hims and Hers (HIMS) July orders fall further - BofA
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put
-
Hims House podcast shares statement from Hims & Hers regarding Bloomberg report
-
After-hours movers: UnitedHealth, Applied Materials, Intel, Hims & Hers Health
-
Hims & Hers Health, Inc. (HIMS) Probed By US FTC Over Cancellation Practices - Bloomberg
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.6 calls to 1 put with a focus on August 55 calls
-
HIMS Shares Decline Amid Lower Revenue Per Order For GLP-1 Following Novo Nordisk Collaboration Termination, Securities Class Action Pending -- Hagens Berman
-
Popular stocks volume: HIMS INTC SNAP OPEN UNH SMCI RIVN HOOD COIN UBER MSTR PFE
-
Novo Nordisk files 14 new lawsuits over compounded semaglutide drugs
-
Hims & Hers Health, Inc. (HIMS) on Watch; Novo Nordisk (NVO) Expands Legal Action to Protect US Patients From Non-FDA-approved Compounded 'Semaglutide'
-
Popular stocks volume: HIMS HOOD PFE SMCI SOFI COIN
-
BTIG Reiterates Buy Rating on Hims and Hers (HIMS), PT $85
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $28
-
Truist on Hims and Hers (HIMS): 'Revs Below As Core Growth Continues to Soften'
-
Hims and Hers (HIMS) PT Raised to $48 at TD Cowen
-
Hims and Hers (HIMS) PT Raised to $43 at Leerink Partners
-
After-hours movers: Palantir, Hims & Hers, Vertex Pharma and more
-
Hims & Hers Health (HIMS) Tops Q2 EPS by 2c, Revenue Misses, Offers Guidance
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1.4 puts into quarter results
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1.6 puts into quarter results
-
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy(R) - Hagens Berman
-
Hims & Hers reports weight loss data for compounded GLP-1 treatments
-
Hims & Hers Health, Inc. (HIMS) options active on 310K contracts
-
Hims & Hers (HIMS) reportedly makes statement on congressional letter to FDA
-
Hims & Hers Health, Inc. (HIMS) Alleged "Deceptive" Marketing of Wegovy(R) Triggers Securities Class Actions - HIMS Investors with Losses Encouraged to Contact Hagens Berman
-
Hims & Hers Health, Inc. (NYSE: HIMS) Falls, Group Of 81 Bipartisan Lawmakers Sign Letter On Glp-1 Action
-
Popular stocks with increasing volume: HIMS MSTR RKT AAL PLTR NIO HOOD COIN LCID SOFI MRNA
